Spark Therapeutics

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Adapting to the anticounterfeiting packaging landscape Packaging specialist at Sumitomo (SHI) Demag UK, Ashlee Gough, examines the latest techniques being deployed to counteract infringements in the pharmaceutical sector and...
  2. Novavax sells protein manufacturing facility to Novo Nordisk for $200m Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support...
  3. Ann-Xiaoyan Li appointed new Group CFO and Managing Director of the Romaco Group New member on the Romaco Group Board of Management
  4. Farmak International expands its sterile therapeutic production capacity with new Barcelona facility The site has R&D, production, logistics, packaging and cold storage space to allow for scalable, end-to-end pharmaceutical manufacturing
  5. Leon Nanodrugs' FR-JET nanoparticle technology proves effective in feasibility study The company's nanoencapsulation technology worked efficiently with a broad operating window, and was deemed scalable by nanoformulation experts at Evonik Canada

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Media

Licensing and supply agreement for voretigene neparvovec outside the US

Spark Therapeutics announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialise investigational voretigene neparvovec outside the US, while Spark Therapeutics will continue to exclusively commercialise Luxturna (voretigene neparvovec-ryzl) in the US
Recruitment

Spark Therapeutics announces addition to Board of Directors
Regulatory

Price tag of $850,000 set for Luxturna gene therapy

The US Food and Drug Administration approved Luxturna last month, a new gene therapy to treat children and adult patients with an inherited form of vision loss that may result in blindness but the price has only just be revealed
Research & Development

Pfizer expands rare disease research with establishment of gene therapy platform

Appoints Michael Linden to head its genetic research into rare diseases
Subscribe now